202 related articles for article (PubMed ID: 16038981)
1. Involving the pharmaceutical and biotech communities in medication development for substance abuse.
Gorodetzky CW; Grudzinskas C
Pharmacol Ther; 2005 Oct; 108(1):109-18. PubMed ID: 16038981
[TBL] [Abstract][Full Text] [Related]
2. Gender issues and the pharmacotherapy of substance abuse.
Heading CE
IDrugs; 2008 Jun; 11(6):428-32. PubMed ID: 18509784
[TBL] [Abstract][Full Text] [Related]
3. The economics of pediatric formulation development for off-patent drugs.
Milne CP; Bruss JB
Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
[TBL] [Abstract][Full Text] [Related]
4. Medications development: successes and challenges.
Vocci F; Ling W
Pharmacol Ther; 2005 Oct; 108(1):94-108. PubMed ID: 16083966
[TBL] [Abstract][Full Text] [Related]
5. The State perspective.
Lipton DS; Appel P
NIDA Res Monogr; 1984; 51():151-66. PubMed ID: 6095082
[TBL] [Abstract][Full Text] [Related]
6. Drug development for children: how is pharma tackling an unmet need?
Hawcutt DB; Smyth RL
IDrugs; 2008 Jul; 11(7):502-7. PubMed ID: 18600597
[TBL] [Abstract][Full Text] [Related]
7. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
8. A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development.
Robinson S; Delongeas JL; Donald E; Dreher D; Festag M; Kervyn S; Lampo A; Nahas K; Nogues V; Ockert D; Quinn K; Old S; Pickersgill N; Somers K; Stark C; Stei P; Waterson L; Chapman K
Regul Toxicol Pharmacol; 2008 Apr; 50(3):345-52. PubMed ID: 18295384
[TBL] [Abstract][Full Text] [Related]
9. Abuse deterrent formulations and the Controlled Substances Act (CSA).
Sapienza FL
Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S23-30. PubMed ID: 16529882
[TBL] [Abstract][Full Text] [Related]
10. Promoting, improving and accelerating the drug development and approval processes.
Graul AI
Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899
[TBL] [Abstract][Full Text] [Related]
11. Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence.
Grabowski J; Shearer J; Merrill J; Negus SS
Addict Behav; 2004 Sep; 29(7):1439-64. PubMed ID: 15345275
[TBL] [Abstract][Full Text] [Related]
12. The history and contemporary challenges of the US Food and Drug Administration.
Borchers AT; Hagie F; Keen CL; Gershwin ME
Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
[TBL] [Abstract][Full Text] [Related]
13. Medication development for addictive disorders: the state of the science.
Vocci FJ; Acri J; Elkashef A
Am J Psychiatry; 2005 Aug; 162(8):1432-40. PubMed ID: 16055764
[TBL] [Abstract][Full Text] [Related]
14. Integration of research in pharmacotherapy for addictive disease: where are we? Where are we going?
Ling W; Shoptaw S
J Addict Dis; 1997; 16(4):83-102. PubMed ID: 9328811
[TBL] [Abstract][Full Text] [Related]
15. If 'atypical' neuroleptics did not exist, it wouldn't be necessary to invent them: perverse incentives in drug development, research, marketing and clinical practice.
Charlton BG
Med Hypotheses; 2005; 65(6):1005-9. PubMed ID: 16182461
[TBL] [Abstract][Full Text] [Related]
16. National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse.
Butler SF; Budman SH; Licari A; Cassidy TA; Lioy K; Dickinson J; Brownstein JS; Benneyan JC; Green TC; Katz N
Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1142-54. PubMed ID: 18932173
[TBL] [Abstract][Full Text] [Related]
17. Risk evaluation and mitigation strategies for drugs with abuse liability: public interest, special interest, conflicts of interest, and the industry perspective.
Wright C; Schnoll S; Bernstein D
Ann N Y Acad Sci; 2008 Oct; 1141():284-303. PubMed ID: 18991964
[TBL] [Abstract][Full Text] [Related]
18. Drug abuse treatment programs in the Federal Bureau of Prisons: initiatives for the 1990s.
Murray DW
NIDA Res Monogr; 1992; 118():62-83. PubMed ID: 1620227
[TBL] [Abstract][Full Text] [Related]
19. Pediatric exclusivity: evolving legislation and novel complexities within pediatric therapeutic development.
Rivera DR; Hartzema AG
Ann Pharmacother; 2014 Mar; 48(3):369-79. PubMed ID: 24311725
[TBL] [Abstract][Full Text] [Related]
20. Targeted lipidomics and drug abuse research.
Rapaka RS
Prostaglandins Other Lipid Mediat; 2005 Sep; 77(1-4):219-22. PubMed ID: 16099406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
